Unaudited Standalone Financial Results Of The Company Forthe Second Quarter And Half Year Ended 30 September2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.5 pts less than Nifty Microcap 250 and 3.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Zenith Healthcare reported Q2 FY26 revenue from operations of ₹226.66 lakhs, down from ₹302.79 lakhs in Q2 FY25 — a drop of about 25% year-on-year. Despite the topline decline, net profit for the quarter rose to ₹14.18 lakhs versus ₹9.34 lakhs in the year-ago quarter, helped by lower operating expenses. However, Q1 FY26 had slipped into a small loss of ₹1.88 lakhs, pulling half-year PAT down to around ₹12.30 lakhs. The auditor (Doshi Doshi & Co) issued an unmodified limited review report with no qualifications. Operating cash flow for the half year turned negative at ₹(32.85) lakhs, mainly due to a sharp increase in loans given and working capital outflows, though investing activities brought in ₹21 lakhs from matured fixed deposits.
Mixed picture for shareholders — profitability improved in Q2 but revenue is shrinking and the company is burning cash from operations, which raises questions about working capital and loan-recovery risk. Short-term stock reaction may be muted; investors should watch whether revenue stabilises and operating cash flow turns positive in H2.